The Rogosin Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, The Rogosin Institute sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
The Rogosin Institute: 21 sponsored US clinical trials, 3 recruiting.
The Rogosin Institute sponsors 21 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 16 completed. 2 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Elevated Triglycerides, with 1 trials.
Top-decile sponsor footprint
The Rogosin Institute ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
21 total, page 1 of 1
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
NCT01802034
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
NCT01109368
Polycystic Kidney Disease Data Repository
NCT00792155
Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
NCT05540457
A Guided Meditation Program in Patients Undergoing Dialysis
NCT04155216
Anxiety and Symptom Burden in Hemodialysis Patients
NCT04143100
Procalcitonin and Brain Natriuretic Peptides in Patients With Chronic Kidney Disease.
NCT03698877
Fructose-induced Hepatic De Novo Lipogenesis in Adolescents With Obesity
NCT03567837
Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer
NCT03229265
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
NCT03102632
Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients
NCT02046174
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping
NCT02161068
Treatment Modification to Reduce Symptom Burden in Hemodialysis
NCT01775800
Change of Fructose to Fat in South Asians
NCT01562782
Pilot Study of Velcade® in IgA Nephropathy
NCT01103778
Inflammatory and Immune Profiling of Kidney Tissue Obtained From Patients With Newly Diagnosed Kidney Disease
NCT01156428
Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T
NCT01174368
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
NCT01053013
Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease
NCT01114594
Combined Renin Inhibition/Beta-blockade
NCT00627861
Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer
NCT00283075
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the The Rogosin Institute pipeline
3 recruiting of 21 indexed (14% open); 16 completed (76%).
Phase mix: 2 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Elevated Triglycerides (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
The Rogosin Institute: open-pipeline peers nationwide
Peers matched on 21 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
The Rogosin Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 trials (± recruiting share)
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this The Rogosin Institute page
21 registered trials is a research-attention snapshot, not an endorsement of The Rogosin Institute or any single study.
- 3 of The Rogosin Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Elevated Triglycerides is the condition The Rogosin Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Elevated Triglycerides trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
The Rogosin Institute pipeline card: 21 registered trials from official public datasets.Report a data error.